← Eichor
Study identifier: NCT06002659 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)

Condition: B-cell Lymphoma  ·  Sponsor: Uppsala University

PhasePhase 1/Phase 2
Planned participants18
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

The purpose is to study the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of CAR20(NAP)-T for patients with B-cell malignancies.

This description comes directly from the study's public registry record.

Talk to the study team

Gunilla Enblad, MD/PhD  ·  +46186110000  ·  gunilla.enblad@igp.uu.se

Di Yu, PhD  ·  +46707204196  ·  di.yu@igp.uu.se

Always discuss trial participation with your own doctor first.

Locations (2)

Karolinska University HospitalStockholm, SwedenActive Not Recruiting
Uppsala University HospitalUppsala, SwedenRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06002659